Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT0180 in Advanced Hepatocellular Carcinoma
NCT04756648Phase 1Active, not recruiting
- Sponsor
- Zhejiang University
- Start
- Mar 2021
- Primary completion
- Mar 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT0180 in hepatocellular carcinoma (HCC), sponsored by Zhejiang University. Primary endpoints: Dose-Limiting Toxicity at 28 days, Maximal Tolerable Dose at 28 days and 2 more. Started Mar 2021; status: active, not recruiting.
02
Drugs
CT0180
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04756648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04756648.